att4_Rice_Sep07

1,049 views

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,049
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
27
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • att4_Rice_Sep07

    1. 1. Heparin-Induced Thrombocytopenia <ul><li>Lawrence Rice, MD </li></ul><ul><li>Chief, Division of Hematology </li></ul><ul><li>Clinical Chief, Hem/Onc Service </li></ul><ul><li>The Methodist Hospital </li></ul><ul><li>Weill Cornell Medical College </li></ul><ul><li>Houston, Texas </li></ul>
    2. 2. DVT in a Breast Cancer Patient <ul><li>69-year-old woman, first Dx Breast Ca in 2002, on and off chemotherapy last 2 years for recurrent pleural metastases </li></ul><ul><li>First left leg DVT in March ‘06 </li></ul><ul><li>July ’06 Admitted for progressive leg pain and swelling, worse DVT, despite outpatient warfarin Rx IV heparin, IVC filter (platelets 350K) </li></ul><ul><li>Two weeks later: Discharged on warfarin (platelets 81K; had been ~80K last several days) </li></ul>
    3. 3. HIT With Cancer
    4. 4. Some Lessons from this Case <ul><li>HIT is a common problem </li></ul><ul><li>HIT engenders an extreme risk for serious thrombotic complications </li></ul><ul><li>Unopposed warfarin increases this risk </li></ul><ul><li>IVC filters should be avoided </li></ul><ul><li>Alternative anticoagulants should be started expeditiously </li></ul><ul><li>Therefore, clinicians must be highly informed and remain vigilant for HIT </li></ul>
    5. 5. There are more than 100 HIT stories in the Medical Center every year…
    6. 6. Frequency of HIT Perspectives <ul><li>More than 1 trillion units heparin used yearly in US; 1/3 of hospitalized exposed (12 million) </li></ul><ul><li>Unfractionated heparin – 3 - 5% incidence; Heart surgery 2.5% incidence </li></ul><ul><li>LMWHeparin, Catheter-flushes -- ~0.5% </li></ul><ul><li>Warkentin, NEJM ’95, 11/332 SQ heparin v. 0/333 LMWH developed HIT </li></ul><ul><li>Laster, 1988, 10/2,000 (0.5%) HIT exposed only to coated vascular catheter </li></ul><ul><li>Frequency of thromboemboli – 30-75% </li></ul>
    7. 7. Some Paradoxes of HIT <ul><li>Heparin, the most powerful anticoagulant of the twentieth Century, saving uncountable lives and limbs, also produces the most extreme hypercoagulable disorder, costing thousands yearly their lives and limbs. </li></ul><ul><li>HIT, an immune reaction to an anticoagulant that lowers platelet count, rarely causes bleeding, </li></ul><ul><li>it causes thromboses,(and platelet transfusions are contraindicated). </li></ul><ul><li>Health professionals should be knowledgeable about a reaction that is common, often catastrophic, preventable, treatable, iatrogenic, and a major source of litigation, yet textbooks and medical curriculae pay little attention, </li></ul><ul><li>and prevailing lack of awareness is shocking. </li></ul>
    8. 8. Heparin-Induced Thrombocytopenia (HIT): Pathophysiology 1 *Places patient at greater risk from primary thrombotic problem. 1. Adapted from Aster RH. N Engl J Med . 1995;332(20):1374-1376. Formation of PF4-heparin complexes IgG antibody Formation of immune complexes (PF4-heparin-IgG) EC injury PF4 release Platelet activation* Microparticle release Fc receptor Platelet Heparin-like molecules Blood vessel PF4 Heparin
    9. 9. Heparin-Induced Thrombocytopenia (HIT): Clinical Consequences if Untreated <ul><li>Sequelae Incidence </li></ul><ul><li>New thromboses ~50% </li></ul><ul><li>(arterial or venous) </li></ul><ul><li>Amputation ~21% </li></ul><ul><li>Death ~30% </li></ul>1. Warkentin TE, Kelton JG. Am J Med. 2. King DJ, Kelton JG. Ann Intern Med.
    10. 10. Risk of Thrombosis with HIT After Heparin is Stopped (if an effective alternative is not begun) Warkentin and Kelton. Am J Med 1996;101. Days after isolated HIT recognized 100 90 80 70 60 50 40 30 20 10 0 52.8% 0 2 4 6 10 12 14 16 8 18 22 26 28 30 24 20 Cumulative frequency of thrombosis (%)
    11. 11. HIT is a Clinico-Pathologic Syndrome <ul><li>Fall in platelet counts (generally >50%) </li></ul><ul><li>Appropriate time after heparin initiation (5-12 days) </li></ul><ul><li>Extreme risk for venous or arterial thromboembolic complications </li></ul><ul><li>Eventually: </li></ul><ul><li>Serologic confirmation of platelet-activating heparin-PF4 antibodies </li></ul>
    12. 12. Clinical Suspicion for HIT The 4 T’s (Warkentin, 2003) <ul><li>Thrombocytopenia </li></ul><ul><li>Timing </li></ul><ul><li>Thrombosis </li></ul><ul><li>oTher causes for low platelets </li></ul><ul><li>award 0–2 points for how typical for HIT </li></ul><ul><li>high prob 6–8 pts; intermed 4-5; low 0-3 </li></ul><ul><li>The 5 th T: The Test </li></ul>
    13. 13. HIT Temporal Variants Courtesy of Dr Ahjad AlMahameed Cleveland Clinic, OH. Day 1 Day 4 Day 14 Day 30 Delayed-onset HIT (9 – 40 days) Rapid-onset HIT (hours – days) Typical HIT Mean Day 9 (4 – 14 days) Heparin (re) Exposure THROMBOCYTOPENIA (± THROMBOSIS)
    14. 14. Distribution of Platelet Count Warkentin. Semin Hematol 1998;35(4):9-16.
    15. 15. Laboratory Tests for Heparin-PF4 Antibodies <ul><li>Commercially available ELISAs Highly sensitive (95-99%); High “false positive” rates; titer important </li></ul><ul><li>Serotonin-release assays Technically demanding; variation lab- to-lab; limited availability </li></ul><ul><li>Platelet aggregation assays Poor reproducibility </li></ul><ul><li>Multiple others Flow cytometry or fluorescence-based Rapid bedside immunoassays </li></ul><ul><li>Newer tests in development </li></ul>
    16. 16. ACCP Antithrombotic Guidelines Chest supplement, Sept. 2004, Chapter on HIT: Monitoring, Dx and Rx <ul><li>Examples of Evidence-Based Recommendations: </li></ul><ul><li>“ postoperative prophylaxis with UFheparin (HIT risk > 1%), at least every other day platelet count monitoring between post-op days 4-14 or until UFH is stopped (2C)” </li></ul><ul><li>“ postoperative prophylaxis with LMWheparin (HIT risk 0.1-1%), platelet count monitoring every 2 to 3 days between days 4-14 (2C)” </li></ul>
    17. 17. Treatment of Other Drug-Induced Thrombocytopenias <ul><li>Stop the drug </li></ul><ul><li>Consider platelet transfusions </li></ul><ul><li>Consider other measures to reduce bleeding risk </li></ul><ul><li>Once platelets rise, the reaction is over </li></ul><ul><li>Stop all heparin exposures </li></ul><ul><li>Initiate an alternative anticoagulant on suspicion </li></ul><ul><li>Do NOT transfuse platelets; initiate warfarin early </li></ul><ul><li>Risk of thrombosis extends weeks after platelet recovery </li></ul>Treatment of Heparin-Induced Thrombocytopenia Rice L. Arch Intern Med. 2004;164:1961-1964.
    18. 18. Alternative Anticoagulants Approved for HIT in Canada, Europe, Aust. Danaparoid Prophylaxis and Rx of VTE Fondaparinux (pentasac.) PCI (including HIT patients) Bivalirudin FDA-approved for HIT Lepirudin FDA-approved for HIT (also for PCI) Argatroban Indications Drug
    19. 19. The Key to Avoiding Catastrophes from HIT is Awareness, Vigilance, High Degree of Suspicion <ul><li>When a patient... </li></ul><ul><ul><li>experiences a drop in platelet counts </li></ul></ul><ul><ul><li>develops thrombosis </li></ul></ul>Consider HIT during/soon after heparin exposure* * Heparin exposure may be through virtually any preparation (including LMWH), any dose, or any route of heparin (including flushes and coated lines)
    20. 20. HIT Summary <ul><li>A distinct clinico-pathologic syndrome </li></ul><ul><li>Common—among most common causes of thrombocytopenia in hospital </li></ul><ul><li>Serious, always potentially catastrophic </li></ul><ul><li>Unique pathophysiology and testing </li></ul><ul><li>Unique complication profile: Thromboemboli </li></ul><ul><li>Unique management: alternative anticoagulants </li></ul>
    21. 21. Proposed ICD-9 CM <ul><li>New Code </li></ul><ul><ul><li>289.84 Heparin-induced thrombocytopenia (HIT) </li></ul></ul><ul><li>A new 5 digit subclassification code as follows: </li></ul><ul><ul><li>287 Purpura and other hemorrhagic conditions </li></ul></ul><ul><ul><ul><li>287.4 Secondary thrombocytopenia </li></ul></ul></ul><ul><ul><ul><ul><li>Post-transfusion purpura </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Thrombocytopenia (due to): </li></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Dilutional </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Drugs </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Extracorporeal circulation of blood </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Platelet alloimmunization </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><li>Use addition E code to identify cause </li></ul></ul></ul></ul><ul><ul><ul><li>Add Excludes: Heparin-induced thrombocytopenia (289.84) </li></ul></ul></ul>
    22. 22. Proposed ICD-9 CM <ul><li>A new 5 digit subclassification code as follows: </li></ul><ul><ul><li>289 Other diseases of blood and blood-forming organs </li></ul></ul><ul><ul><ul><li>289.8 other specified diseases of blood and blood-forming organs </li></ul></ul></ul><ul><ul><ul><ul><li>289.81 Primary hypercoagulable state </li></ul></ul></ul></ul><ul><ul><ul><ul><li>289.82 Secondary hypercoagulable state </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Add Excludes: Heparin-induced thrombocytopenia (289.84) </li></ul></ul></ul></ul><ul><ul><ul><ul><li>289.83 Myleofibrosis </li></ul></ul></ul></ul><ul><ul><li>New Code </li></ul></ul><ul><ul><ul><ul><li>289.84 Heparin-induced thrombocytopenia (HIT) </li></ul></ul></ul></ul>

    ×